speb/financial-data huggingface dataset:
THEMISMED.NS cash_flow (annual, 2022-03-31) — Investing Cash Flow: -155859000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Investmentin Financial Assets: 20463000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Investmentsin Associatesat Cost: 285654000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Investmentsin Joint Venturesat Cost: 275185000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Issuance Of Capital Stock: 3955000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 615344000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Long Term Capital Lease Obligation: 19942000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Long Term Debt: 223069000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Long Term Debt And Capital Lease Obligation: 243011000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Long Term Equity Investment: 560839000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 1037841000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Minority Interest: -7000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Minority Interests: 1000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Net Common Stock Issuance: 3955000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Net Debt: 563880000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Net Foreign Currency Exchange Gain Loss: 0.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Net Income: 728808000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Net Income Common Stockholders: 728808000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Net Income Continuous Operations: 728807000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Net Income From Continuing And Discontinued Operation: 728808000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Net Income From Continuing Operation Net Minority Interest: 728808000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Net Income From Continuing Operations: 952620000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Net Income Including Noncontrolling Interests: 728807000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Net Interest Income: -81690000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Net Investment Purchase And Sale: 0.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: -66066000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: 16851000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Net Non Operating Interest Income Expense: -81690000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Net PPE: 1455741000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Net PPE Purchase And Sale: -193047000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Net Short Term Debt Issuance: -82917000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Net Tangible Assets: 2865003000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Liabilities: 64724000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 69036000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Normalized EBITDA: 1112448000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Normalized Income: 728548646.25
THEMISMED.NS cash_flow (annual, 2022-03-31) — Operating Cash Flow: 343941000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Operating Income: 861552000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Operating Revenue: 3913480000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Ordinary Shares Number: 92002700.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Current Assets: 10464000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Current Liabilities: 40349000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Equity Interest: 2373000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Intangible Assets: 9888000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Other Non Cash Items: 65369000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Non Current Assets: 89314000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Other Non Operating Income Expenses: 12646000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Other Operating Expenses: 661814000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Payable: 123582000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Properties: 51317000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 7671000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Other Short Term Investments: 111616000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Payables: 481920000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 18604000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 244710000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Pretax Income: 952620000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Purchase Of Investment: 0.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Purchase Of PPE: -206273000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 243403000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Reconciled Cost Of Revenue: 1519946000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Reconciled Depreciation: 94798000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 9794000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 9794000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 62200000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 1408403000.00
THEMISMED.NS cash_flow (annual, 2022-03-31) — Sale Of PPE: 13226000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 179291000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 278512000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Share Issued: 92002700.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Special Income Charges: 0.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Stockholders Equity: 2874891000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Tangible Book Value: 2865003000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: 79646.25
THEMISMED.NS income_statement (annual, 2022-03-31) — Tax Provision: 223813000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.23
THEMISMED.NS cash_flow (annual, 2022-03-31) — Taxes Refund Paid: -180737000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Total Assets: 4277805000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Total Capitalization: 3097960000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Total Debt: 797324000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: 2874884000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Total Expenses: 3051928000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 1402921000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Total Non Current Assets: 2136245000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Total Non Current Liabilities Net Minority Interest: 307735000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 22376000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Total Tax Payable: 34609000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Total Unusual Items: 339000.00
THEMISMED.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: 339000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Work In Process: 149194000.00
THEMISMED.NS balance_sheet (annual, 2022-03-31) — Working Capital: 1046374000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — +Operating Expense: 1665021000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — +Total Revenue: 3444550000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 400447000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 1450240000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -572871000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 355256000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: 0.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Amortization: 2184000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 2184000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 3724000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Average Dilution Earnings: 0.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 92027700.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Basic EPS: 6.18
THEMISMED.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 202793000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 225442000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -287479000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 25224000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 92028000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 125465000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 125465000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -46001000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 125465000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -81426000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -40538000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 76591000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Change In Payable: 81709000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -444612000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -402961000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -77328000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Common Stock: 92028000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 3394423000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 837000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 26001000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 1209968000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Current Assets: 2645299000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 7749000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Current Debt: 631548000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 639297000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 1391285000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 23919000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Defined Pension Benefit: 14484000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Depreciation: 102764000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 104948000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 104948000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 102764000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 92180107.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Diluted EPS: 6.17
THEMISMED.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 569008000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 975000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Dividends Received Cfi: 42051000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — EBIT: 805051000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — EBITDA: 909999000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — End Cash Position: 125465000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 2776000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: 1362000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 318500000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Fixed Assets Revaluation Reserve: 337716000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: -126554000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -48053000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of Business: 1000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -212000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 93445000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 7704000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 1450240000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 2213199000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Gross Profit: 2234582000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Interest Expense: 79902000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 79902000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Interest Income: 5473000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 5473000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -79902000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 5473000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Inventory: 689520000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 4292951000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -239615000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 6500000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Investments In Other Ventures Under Equity Method: 697162000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Investmentsin Associatesat Cost: 391917000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Investmentsin Joint Venturesat Cost: 305245000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 837000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 615344000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 17475000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 266980000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 284455000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 697162000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 1293855000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Minority Interest: -9000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Minority Interests: 2000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: 837000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Net Debt: 773063000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -117000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Net Income: 569010000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 569010000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 569008000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 569010000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 569010000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 725149000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 569008000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Net Interest Income: -90171000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: 0.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 134063000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 45635000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -90171000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Net PPE: 1640328000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -287139000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 88428000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 3386719000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 69407000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 128084000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 909470000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Normalized Income: 568594905.68
THEMISMED.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 160925000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Operating Income: 569561000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Operating Revenue: 3444550000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 92027700.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 10522000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 44349000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 650000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 7704000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 79902000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 142568000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 34726000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 715479000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Payable: 200798000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Properties: 52557000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 1661000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 112623000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Payables: 683720000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 23919000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 304501000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Pretax Income: 725149000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: 0.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -287479000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 246880000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 1209968000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 104948000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 18077000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 18077000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 63390000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 1932941000.00
THEMISMED.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 340000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 170302000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 263747000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Share Issued: 92027700.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Special Income Charges: 0.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 3394423000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 3386719000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 113905.68
THEMISMED.NS income_statement (annual, 2023-03-31) — Tax Provision: 156141000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.22
THEMISMED.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -161548000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Total Assets: 5139561000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 3661403000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Total Debt: 923752000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 3394414000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Total Expenses: 2874989000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 1745147000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 2494262000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 353862000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 15742000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 81500000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 529000.00
THEMISMED.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 529000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Work In Process: 124140000.00
THEMISMED.NS balance_sheet (annual, 2023-03-31) — Working Capital: 1254014000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — +Operating Expense: 1976134000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — +Total Revenue: 3766324000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 472923000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 1779455000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -691713000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 355659000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: 0.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Amortization: 2184000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 2184000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 9373000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Average Dilution Earnings: 0.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 92040120.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Basic EPS: 4.73
THEMISMED.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 125465000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 240820000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -184179000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 20819000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 92040000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 99217000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 99217000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -46014000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 99217000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -16223000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 27160000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 30274000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Change In Payable: 72476000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -329215000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -209163000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -26248000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Common Stock: 92040000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 3776666000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 415000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 26018000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 1397601000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Current Assets: 2931680000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 4410000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Current Debt: 685772000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 690182000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 1529809000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 25645000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Defined Pension Benefit: 0.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Depreciation: 122463000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 122463000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 122463000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 120279000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 92205727.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Diluted EPS: 4.72
THEMISMED.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 435238000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 1293000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 16057000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — EBIT: 610707000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — EBITDA: 733170000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — End Cash Position: 99217000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 3677000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -87704000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 324836000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Fixed Assets Revaluation Reserve: 333714000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 36757000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -25353000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of Business: 0.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -174000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 108979000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 5520000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 1779455000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 2395866000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Gross Profit: 2368723000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Interest Expense: 76275000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 76275000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Interest Income: 8393000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 8393000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -76275000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 8393000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Inventory: 705743000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 4713769000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -159480000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 13050000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 513308000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Investmentsin Joint Venturesat Cost: 371808000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 415000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 615344000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 16409000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 251331000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 267740000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 885116000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 1458943000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Minority Interest: -12000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Minority Interests: 3000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 415000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Net Debt: 837886000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 72000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Net Income: 435238000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 435238000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 435235000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 435238000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 435238000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 534432000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 435235000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Net Interest Income: -85373000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 0.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 38361000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -16715000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -85373000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Net PPE: 1704153000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -183930000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 55076000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 3771146000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 73925000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 16037000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 732267000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Normalized Income: 434502607.65
THEMISMED.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 220936000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Operating Income: 392589000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Operating Revenue: 3766324000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 92040120.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 10521000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 42973000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 3684626000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 5520000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 76275000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 124646000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 5481000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 726590000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Payable: 229856000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Properties: 54741000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 1661000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 144798000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Payables: 787046000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 9608000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 241339000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Pretax Income: 534432000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: 0.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -184179000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 247399000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 1397601000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 122463000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 21692000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 21692000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 93744000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 2319349000.00
THEMISMED.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 249000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 223590000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 332569000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Share Issued: 92040120.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Special Income Charges: 0.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 3776666000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 3771146000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 167607.65
THEMISMED.NS income_statement (annual, 2024-03-31) — Tax Provision: 99197000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.19
THEMISMED.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -89562000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Total Assets: 5664165000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 4027997000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Total Debt: 957922000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 3776654000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Total Expenses: 3373735000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 1887511000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 2732485000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 357702000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 17491000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 82974000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 903000.00
THEMISMED.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 903000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Work In Process: 133508000.00
THEMISMED.NS balance_sheet (annual, 2024-03-31) — Working Capital: 1401871000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 529853000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 2006609000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 14135000.00
THEMISMED.NS income_statement (quarterly, 2024-09-30) — Basic Average Shares: 92214839.00
THEMISMED.NS income_statement (quarterly, 2024-09-30) — Basic EPS: 1.55
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 0.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 92040000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 96995000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 232274000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 92040000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 4120152000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 32441000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 3120946000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 0.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 575609000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 575609000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 1584148000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 24448000.00
THEMISMED.NS income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 92214839.00
THEMISMED.NS income_statement (quarterly, 2024-09-30) — Diluted EPS: 1.55
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 4428000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 1765734000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 645538000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 4934690000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 14135000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 0.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 238929000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 238929000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 989290000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: -13000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 717543000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 1765734000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 4115724000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 78928000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 92040120.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 236525000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 8603000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 4028112000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 127611000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 1733293000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 135279000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Payables: 683053000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 92040120.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 4120152000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 4115724000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 6022144000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 4359081000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 814538000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 4120139000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 1902005000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 2901198000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 317857000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 153200000.00
THEMISMED.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 1536798000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 593197000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 938063000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 86550000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 0.06
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 284979000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 25403000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 25403000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 86550000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.06
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 5193000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — EBIT: 44485000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — EBITDA: 69888000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 653084000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 27881000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 27881000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Minority Interests: 0.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Net Income: 5193000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 5193000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 5193000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 5193000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 5193000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 5193000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -27881000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -27881000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 69888000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 5193000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Operating Income: 59887000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 938063000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 10217000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 318253000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 16604000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 284979000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 25403000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 11411000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.30
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 878176000.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
THEMISMED.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
THEMISMED.NS income_statement (annual, 2025-03-31) — +Operating Expense: 2344015000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 594292000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — +Total Revenue: 4055116000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 717016000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 514375000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 514375000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 1771024000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 1771024000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -782261000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -782261000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 355659000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 355659000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: 0.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Amortization: 2184000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 2184000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 11835000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 11835000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Average Dilution Earnings: 0.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 92077160.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 92041905.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Basic EPS: 3.24
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Basic EPS: -1.05
THEMISMED.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 99217000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 257182000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 257182000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -154264000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 23919000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 23919000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 92040000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 92040000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 65594000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 65594000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 65594000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 65594000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -46020000.00